Get the Stockscreener App
0.5671
3.88%
-0.0229
Vor Biopharma Inc stock is traded at $0.5671, with a volume of 297.77K.
It is down -3.88% in the last 24 hours and down -35.56% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$0.59
Open:
$0.59
24h Volume:
297.77K
Relative Volume:
0.59
Market Cap:
$70.80M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-0.3458
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-24.68%
1M Performance:
-35.56%
6M Performance:
-15.52%
1Y Performance:
-72.74%
1-Day Range:
$0.5527
$0.61
1-Week Range:
$0.5527
$0.761
52-Week Range:
$0.5527
$2.22
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.5671 | 70.80M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Biopharma CMO resigns to pursue new opportunity - Investing.com Australia
Vor Biopharma’s Chief Medical Officer Resigns - TipRanks
Vor Bio Advances in Clinical Trials and Secures Funding - TipRanks
Vor Biopharma stock plunges to 52-week low of $0.63 - Investing.com
Vor Biopharma stock plunges to 52-week low of $0.63 By Investing.com - Investing.com South Africa
Virtu Financial LLC Makes New $60,000 Investment in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of “Buy” from Analysts - Defense World
Oppenheimer Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - MarketBeat
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress By Investing.com - Investing.com Canada
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress - Investing.com India
Vor Biopharma stock holds $6 target, Market Outperform rating By Investing.com - Investing.com South Africa
Vor Biopharma stock holds $6 target, Market Outperform rating - Investing.com India
Citizens JMP Reiterates Market Outperform Rating on Vor Biopharma, Inc. (VOR) - StreetInsider
Vor Biopharma (NYSE:VOR) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus - The AM Reporter
Stifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price - Defense World
Oppenheimer Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Wedbush Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating By Investing.com - Investing.com South Africa
Vor Biopharma, Inc. (VOR) PT Lowered to $5 at Stifel - StreetInsider.com
Vor Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - MarketScreener
Vor Biopharma (VOR) Files $350M Mixed Shelf - StreetInsider.com
Vor Biopharma Inc. SEC 10-K Report - TradingView
Vor Biopharma Inc. (VOR) reports earnings - Quartz
Vor Biopharma revises stock option exercise prices - MSN
Vor Biopharma Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
BenitecAnother Biopharma Rocket - Barchart
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now (VOR) - Seeking Alpha
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - ACCESS Newswire
Vor biopharma chief medical officer sells $3,162 in stock By Investing.com - Investing.com Canada
Vor biopharma chief medical officer sells $3,162 in stock - Investing.com India
Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials - Yahoo Finance
Vor biopharma’s chief medical officer sells $3,498 in stock By Investing.com - Investing.com Nigeria
Vor biopharma's chief medical officer sells $3,498 in stock - MSN
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $11.36 - MarketBeat
Following A 1.65% Weekly Incline, Is It Still A Buy For Nerdy Inc (NYSE: NRDY)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Should Energy Vault Holdings Inc (NYSE: NRGV) Rally After -60.12% Drop From High? - Marketing Sentinel
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL): How Can A Stock Be Up 7.83% Year To Date, But Still Loser - Marketing Sentinel
Vor Biopharma revises stock option exercise prices By Investing.com - Investing.com Canada
VOR Shares Experience Surge in Value - Knox Daily
Vor Biopharma Approves Stock Option Repricing Strategy - TipRanks
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):